Abstract
A total of 21 patients with hematologic malignancies were given thiabendazole for treatment of strongyloidiasis. Fifteen patients were cured. Since there were no relapses, it is unlikely that maintenance therapy has a role in the management of strongyloidiasis in this population of patients.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antinematodal Agents / adverse effects
-
Antinematodal Agents / therapeutic use*
-
Child
-
Dizziness / chemically induced
-
Female
-
Follow-Up Studies
-
Hematologic Neoplasms / complications*
-
Humans
-
Male
-
Middle Aged
-
Patient Compliance
-
Strongyloidiasis / complications
-
Strongyloidiasis / drug therapy*
-
Thiabendazole / adverse effects
-
Thiabendazole / therapeutic use*
-
Treatment Outcome
Substances
-
Antinematodal Agents
-
Thiabendazole